Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTNM NASDAQ:OCGN NASDAQ:PRTA NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$14.15+3.6%$13.29$3.35▼$16.33$510.70M0.89289,444 shs92,500 shsOCGNOcugen$1.47$1.84$0.64▼$2.73$497.63M2.38.50 million shs4.37 million shsPRTAProthena$9.60+1.8%$10.00$4.32▼$11.80$493.69M-0.23449,199 shs530,784 shsVRCAVerrica Pharmaceuticals$7.37+3.1%$6.02$3.28▼$9.82$122.83M1.5492,948 shs248,661 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics+3.59%-5.29%+10.89%-4.91%+271.39%OCGNOcugen0.00%+1.03%-17.88%+4.26%+109.25%PRTAProthena+1.80%-14.13%-6.89%+8.47%+26.48%VRCAVerrica Pharmaceuticals+3.08%-12.57%+31.14%+32.55%+34.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$14.15+3.6%$13.29$3.35▼$16.33$510.70M0.89289,444 shs92,500 shsOCGNOcugen$1.47$1.84$0.64▼$2.73$497.63M2.38.50 million shs4.37 million shsPRTAProthena$9.60+1.8%$10.00$4.32▼$11.80$493.69M-0.23449,199 shs530,784 shsVRCAVerrica Pharmaceuticals$7.37+3.1%$6.02$3.28▼$9.82$122.83M1.5492,948 shs248,661 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics+3.59%-5.29%+10.89%-4.91%+271.39%OCGNOcugen0.00%+1.03%-17.88%+4.26%+109.25%PRTAProthena+1.80%-14.13%-6.89%+8.47%+26.48%VRCAVerrica Pharmaceuticals+3.08%-12.57%+31.14%+32.55%+34.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTNMContineum Therapeutics 2.50Moderate Buy$19.5037.81% UpsideOCGNOcugen 2.60Moderate Buy$9.75563.27% UpsidePRTAProthena 2.36Hold$21.78126.85% UpsideVRCAVerrica Pharmaceuticals 2.00Hold$17.00130.66% UpsideCurrent Analyst Ratings BreakdownLatest VRCA, CTNM, PRTA, and OCGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/8/2026PRTAProthena CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026PRTAProthena Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $20.004/27/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026CTNMContineum Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/25/2026OCGNOcugen Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.003/25/2026OCGNOcugen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.003/17/2026OCGNOcugen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.003/13/2026PRTAProthena CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform3/13/2026PRTAProthena Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$19.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTNMContineum Therapeutics$50M10.58N/AN/A$6.69 per share2.12OCGNOcugen$4.41M112.84N/AN/A$0.02 per share73.50PRTAProthena$9.68M51.92N/AN/A$5.97 per share1.61VRCAVerrica Pharmaceuticals$35.58M3.56N/AN/A$1.55 per share4.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTNMContineum Therapeutics-$59.98M-$1.95N/AN/AN/AN/A-27.09%-25.64%N/AOCGNOcugen-$67.85M-$0.24N/AN/AN/A-1,192.18%-127,987.80%-135.48%7/30/2026 (Estimated)PRTAProthena-$244.09M-$2.82N/AN/A1.51-260.92%-43.44%-36.87%N/AVRCAVerrica Pharmaceuticals-$17.89M-$1.58N/AN/AN/A-47.97%N/A-39.89%N/ALatest VRCA, CTNM, PRTA, and OCGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026VRCAVerrica Pharmaceuticals-$0.59-$0.41+$0.18-$0.45$4.51 million$5.02 million5/7/2026Q1 2026PRTAProthena-$0.31$0.60+$0.91$0.60$0.81 million$51.08 million5/5/2026Q1 2026CTNMContineum Therapeutics-$0.55-$0.39+$0.16-$0.39N/AN/A5/5/2026Q1 2026OCGNOcugen-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 million3/11/2026Q4 2025VRCAVerrica Pharmaceuticals-$0.43-$0.51-$0.08-$0.57$4.52 million$5.09 million3/5/2026Q4 2025CTNMContineum Therapeutics-$0.50-$0.49+$0.01-$0.49$5.00 millionN/A3/4/2026Q4 2025OCGNOcugen-$0.06-$0.06N/A-$0.06$0.86 million($0.19) million2/19/2026Q4 2025PRTAProthena-$0.45-$0.44+$0.01-$0.40$0.67 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTNMContineum TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTNMContineum TherapeuticsN/A38.0038.00OCGNOcugen4.171.861.06PRTAProthenaN/A10.4310.43VRCAVerrica Pharmaceuticals0.032.592.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTNMContineum TherapeuticsN/AOCGNOcugen10.27%PRTAProthena97.08%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipCTNMContineum Therapeutics11.30%OCGNOcugen3.95%PRTAProthena10.40%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTNMContineum Therapeutics3137.39 million33.16 millionN/AOCGNOcugen80338.52 million325.15 millionOptionablePRTAProthena13052.35 million46.91 millionOptionableVRCAVerrica Pharmaceuticals4017.18 million7.90 millionNo DataVRCA, CTNM, PRTA, and OCGN HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 13 at 7:55 PM | uk.finance.yahoo.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 13 at 8:00 AM | globenewswire.comVerrica Pharmaceuticals Q1 Earnings Call HighlightsMay 12 at 11:06 PM | marketbeat.comVerrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call TranscriptMay 12 at 10:00 PM | seekingalpha.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesMay 12 at 6:16 PM | zacks.comVerrica Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 12 at 4:01 PM | globenewswire.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Rating of "Reduce" by AnalystsMay 12 at 4:39 AM | americanbankingnews.comVerrica Pharmaceuticals (VRCA) Expected to Announce Earnings on TuesdayMay 10, 2026 | americanbankingnews.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the ...May 6, 2026 | theglobeandmail.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual MeetingMay 5, 2026 | globenewswire.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ...May 5, 2026 | bakersfield.comBVerrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026May 5, 2026 | globenewswire.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest UpdateApril 30, 2026 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Reduce" by BrokeragesApril 17, 2026 | marketbeat.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the ...April 10, 2026 | markets.businessinsider.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingApril 9, 2026 | globenewswire.comVerrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 21, 2026 | tmcnet.comVRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law FirmMarch 20, 2026 | businesswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 20, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRCA, CTNM, PRTA, and OCGN Company DescriptionsContineum Therapeutics NASDAQ:CTNM$14.15 +0.49 (+3.59%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$14.12 -0.04 (-0.25%) As of 05/13/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Ocugen NASDAQ:OCGN$1.47 0.00 (0.00%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$1.46 -0.01 (-0.61%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Prothena NASDAQ:PRTA$9.60 +0.17 (+1.80%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$9.60 0.00 (-0.05%) As of 05/13/2026 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Verrica Pharmaceuticals NASDAQ:VRCA$7.37 +0.22 (+3.08%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$7.38 +0.01 (+0.20%) As of 05/13/2026 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
